Published in Ther Clin Risk Manag on August 01, 2008
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med (2000) 13.25
Diabetes and cardiovascular disease. The Framingham study. JAMA (1979) 11.95
Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol (1974) 5.11
Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med (1984) 5.02
Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res (2006) 3.27
Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care (1998) 2.70
The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA (1988) 2.59
Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation (2002) 2.43
Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med (2003) 2.33
Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med (1995) 2.14
Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation (2003) 2.01
The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med (1989) 1.74
Unrecognized myocardial infarction. Ann Intern Med (2001) 1.30
Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care (2006) 1.28
Coronary heart disease in patients with diabetes. N Engl J Med (2000) 1.22
Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol (1997) 1.14
Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care (2005) 1.13
Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cardiol (1990) 1.05
Clinically unrecognized myocardial infarction detected at MR imaging may not be associated with atherosclerosis. Radiology (2007) 1.00
MR imaging of myocardial perfusion and viability. Magn Reson Imaging Clin N Am (2003) 0.98
Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care (1998) 0.96
Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia (2004) 0.93
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care (2006) 0.92
Silent myocardial ischemia is associated with autonomic neuropathy and other cardiovascular risk factors in type 1 and type 2 diabetic subjects, especially in those with microalbuminuria. Endocrine (2005) 0.92
Assessment of myocardial viability by MR imaging. Eur Radiol (2002) 0.88
Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J (1985) 0.87
Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with type 2 diabetes. Diabetes Metab (2005) 0.80
Silent myocardial infarction in women with impaired glucose tolerance: the Northern Sweden MONICA study. Cardiovasc Diabetol (2003) 0.79
Silent coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetol (2003) 0.79
Cardiac magnetic resonance spectroscopy: potential clinical applications. Herz (2000) 0.78
Late gadolinium cardiovascular magnetic resonance in the assessment of myocardial viability. Coron Artery Dis (2005) 0.77
pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics (2011) 16.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One (2010) 6.38
Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 6.07
The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl (2011) 4.39
Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16
SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics (2007) 3.60
Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A (2010) 3.51
Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl (2010) 3.50
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun (2012) 2.84
An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat Biotechnol (2007) 2.59
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol (2010) 1.94
Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol (2007) 1.75
High resolution PTR-TOF: quantification and formula confirmation of VOC in real time. J Am Soc Mass Spectrom (2010) 1.72
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? Expert Rev Proteomics (2009) 1.61
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Stress-induced cardiomyopathy in Sweden: evidence for different ethnic predisposition and altered cardio-circulatory status. Cardiology (2012) 1.56
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging (2014) 1.49
An open-system quantum simulator with trapped ions. Nature (2011) 1.46
In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun (2009) 1.45
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Processing and classification of protein mass spectra. Mass Spectrom Rev (2006) 1.42
Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol (2002) 1.41
Search strategies-identified reports on "off-label" drug use in MEDLINE. J Clin Epidemiol (2012) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol (2012) 1.41
Automated protein identification by tandem mass spectrometry: issues and strategies. Mass Spectrom Rev (2006) 1.40
Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol Cell Proteomics (2007) 1.38
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol (2002) 1.38
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew Chem Int Ed Engl (2012) 1.34
Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain (2011) 1.33
Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer (2012) 1.30
Dissociable network properties of anesthetic state transitions. Anesthesiology (2011) 1.29
Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care (2006) 1.28
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J (2004) 1.25
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Quantum Google in a complex network. Sci Rep (2013) 1.24
Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res (2007) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Health-related quality of life and sense of coherence among elderly patients with severe chronic heart failure in comparison with healthy controls. Heart Lung (2002) 1.23
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Intestinal permeability is associated with visceral adiposity in healthy women. Obesity (Silver Spring) (2011) 1.21
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis (2009) 1.20
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20
EasyProt--an easy-to-use graphical platform for proteomics data analysis. J Proteomics (2012) 1.20
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol (2006) 1.18
Mutation in the Scyl1 gene encoding amino-terminal kinase-like protein causes a recessive form of spinocerebellar neurodegeneration. EMBO Rep (2007) 1.18
Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J (2012) 1.17
Detection of plant volatiles after leaf wounding and darkening by proton transfer reaction "time-of-flight" mass spectrometry (PTR-TOF). PLoS One (2011) 1.15
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol (2008) 1.14
Parallel isotope-based quantification of modified tRNA nucleosides. Angew Chem Int Ed Engl (2009) 1.14
pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol (2007) 1.13
Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke (2004) 1.12
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS (2012) 1.12
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis (2009) 1.10
Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet (2005) 1.10
Relations of adipose tissue CIDEA gene expression to basal metabolic rate, energy restriction, and obesity: population-based and dietary intervention studies. J Clin Endocrinol Metab (2007) 1.10
Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother (2005) 1.10
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med (2002) 1.09
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail (2009) 1.09
Cell death-inducing DFF45-like effector C is reduced by caloric restriction and regulates adipocyte lipid metabolism. Metabolism (2008) 1.08
Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol (2009) 1.07
Reversible bond formation enables the replication and amplification of a crosslinking salen complex as an orthogonal base pair. Nat Chem (2011) 1.07
On-line breath analysis with PTR-TOF. J Breath Res (2009) 1.06
Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol (2009) 1.06
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res (2011) 1.06
Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol (2006) 1.06
Clinical and procedural characteristics associated with higher radiation exposure during percutaneous coronary interventions and coronary angiography. Circ Cardiovasc Interv (2013) 1.05
Tumor necrosis factor-alpha inhibits renin gene expression. Am J Physiol Regul Integr Comp Physiol (2002) 1.05
Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol Metab (2006) 1.04
Alternative pathway for atmospheric particles growth. Proc Natl Acad Sci U S A (2012) 1.02
Polyphenylene Nanostructures. Chem Rev (1999) 1.02
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Structure and function of noncanonical nucleobases. Angew Chem Int Ed Engl (2012) 1.02
Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother (2003) 1.02
Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab (2006) 1.02
Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol (2009) 1.01
Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J (2004) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism (2003) 1.00
Baseline ICAM-1 and VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up. Angiology (2008) 1.00